fda approve gedatolisib for advanced breast cancer
Before Oct 1, 2026
fda approve gedatolisib for advanced breast cancer. Best Yes near 69¢ across 1 platform. Live cross-platform prices. Not financial advice.
Best Yes: 69¢ · Best No: 37¢ · 1 platform
- Kalshi: Yes 69¢ / No 37¢
LIVE
Before Oct 1, 2026
Volume
$426
$0 24h
Platforms
1
Cross-platform pricing
Resolution
Resolves Oct 1, 2026
~107 days left
Category
Culture
Yes
69¢
Kalshi
No
37¢
Kalshi
Opens on best-price platform
Compare & Trade
1 platform
Price History
Loading…
About This Market
If the FDA approves gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer for marketing before Oct 1, 2026, then the market resolves to Yes.
Market Details
ResolutionResolves Oct 1, 2026
Time Left107 days
Status● Active
CategoryCulture
Yes
69¢
Kalshi
Payout 1.4x
No
37¢
Kalshi
Payout 2.7x
Opens on best-price platform
Compare & Trade
1 platformSign in to join the discussion
Sign In